Table 3.
CMY-2 and its mutants | MICs (mg/L) | |||||
---|---|---|---|---|---|---|
CAZ | CZA | FDC | FEP | ATM | MEM | |
pBC SK(−) (control) | 0.25 | 0.12 | 0.06 | <0.03 | 0.12 | <0.03 |
CMY-2 | 16 | 0.12 | 0.12 | 0.12 | 2 | <0.03 |
Single mutants | ||||||
A114E | 8 | 0.25 | 0.12 | 0.25 | 4 | <0.03 |
Q120K | >32 | 0.5 | 0.25 | 0.25 | 4 | <0.03 |
V211S | >32 | 0.25 | 0.12 | 0.12 | 4 | <0.03 |
N346Y | 2 | 0.25 | 0.25 | <0.03 | 0.25 | <0.03 |
Double mutants | ||||||
A114E Q120K | 32 | 1 | 0.5 | 0.25 | 4 | <0.03 |
A114E V211S | >32 | 0.25 | 0.25 | 0.12 | 16 | <0.03 |
A114E N346Y | 16 | 8 | 0.5 | 2 | 2 | <0.03 |
Q120K V211S | >32 | 0.25 | 0.5 | 0.12 | 8 | <0.03 |
Q120K N346Y | 32 | 32 | 1 | 0.25 | 2 | <0.03 |
V211S N346Y | 32 | 4 | 0.5 | 0.5 | 8 | <0.03 |
Triple mutants | ||||||
A114E Q120K V211S | >32 | 2 | 0.5 | 0.25 | 8 | <0.03 |
A114E Q120K N346Y | 32 | 16 | 2 | 1 | 4 | <0.03 |
A114E V211S N346Y | 32 | 16 | 1 | 0.5 | 16 | <0.03 |
Q120K V211S N346Y | >32 | 16 | 1 | 0.25 | 8 | <0.03 |
Quadruple mutant (CMY-185) | ||||||
A114E Q120K V211S N346Y | >32 | 32 | 2 | 0.5 | 16 | <0.03 |
ATM, aztreonam; CAZ, ceftazidime; CZA, ceftazidime/avibactam; FDC, cefiderocol; FEP, cefepime; MEM, meropenem.